Epirubicin and docetaxel as first-line treatment for hormonal receptor positive metastatic breast cancer: the predictive value of luminal subtype: A retrospective cohort analysis

Author： Nelli Fabrizio   Natoli Guido   Moscetti Luca   Massari Annalisa   D’Auria Giuliana   Fabbri Maria A   Frittelli Patrizia   Ruggeri Enzo M  

Publisher： Maney Publishing

ISSN： 1973-9478

Source： Journal of Chemotherapy, Vol.25, Iss.2, 2013-04, pp. : 112-118

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Docetaxel and Epirubicin as First-Line Treatment for Patients with Metastatic Breast Cancer: A Minnie Pearl Cancer Research Network Phase II Trial

By Hainsworth John   Yardley Denise   Spigel David   Meluch Anthony   Rinaldi David   Schnell Frederick   Greco F.  

Cancer Investigation, Vol. 24, Iss. 5, 2006-06 ,pp. : 469-473

Informa Healthcare

Access to resources Recommend Favorite

Multicenter phase II study of trastuzumab in combination with epirubicin and docetaxel as first-line treatment for HER2-overexpressing metastatic breast cancer

By Venturini M.   Bighin C.   Monfardini S.   Cappuzzo F.   Olmeo N.   Durando A.   Puglisi F.   Nicoletto O.   Lambiase A.   Mastro L.  

Breast Cancer Research and Treatment, Vol. 95, Iss. 1, 2006-01 ,pp. : 45-53

Springer Publishing Company

Access to resources Recommend Favorite

Vinorelbine, Epirubicin and Fluorouracil as First-Line Therapy in Metastatic Breast Cancer

By Elomaa Inkeri   Joensuu Heikki   Blomqvist Carl  

Acta Oncologica, Vol. 42, Iss. 4, 2003-01 ,pp. : 309-314

Informa Healthcare

Access to resources Recommend Favorite

Individually tailored treatment with epirubicin and paclitaxel with or without capecitabine as first-line chemotherapy in metastatic breast cancer: a randomized multicenter trial

By Hatschek T.   Carlsson L.   Einbeigi Z.   Lidbrink E.   Linderholm B.   Lindh B.   Loman N.   Malmberg M.   Rotstein S.   Söderberg M.   Sundquist M.   Walz T.   Hellström M.   Svensson H.   Åström G.   Brandberg Y.   Carstensen J.   Fernö M.   Bergh J.  

Breast Cancer Research and Treatment, Vol. 131, Iss. 3, 2012-02 ,pp. : 939-947

Springer Publishing Company

Access to resources Recommend Favorite

Docetaxel plus epirubicin is a highly active, well-tolerated, first-line chemotherapy for metastatic breast cancer: results of a large, multicentre phase II study

By Morales Serafín   Lorenzo Antonio   Ramos Manuel   Ballesteros Pedro   Méndez Miguel   Almanza Concepción   Castellanos Javier   Moreno-Nogueira José   Casal Joaquín   Lizón José   Oltra Amparo   Frau Adolfo   Machengs Ignacio   Galán Antonio   Belón Joaquín   Llorca Cristina  

Cancer Chemotherapy and Pharmacology, Vol. 53, Iss. 1, 2004-01 ,pp. : 75-81

Springer Publishing Company

Access to resources Recommend Favorite